Orbital invasion despite topical anti-metabolite therapy for conjunctival carcinoma.
BACKGROUND
Two cases of conjunctival carcinoma developed orbital invasion during treatment with topical medication.


METHODS
This was a retrospective study from a tertiary ophthalmic oncology unit, performed after informed consent was obtained. The main outcome measurement was orbital invasion.


RESULTS
Two patients treated with topical agents developed orbital invasion.


CONCLUSIONS
While topical agents are important in treatment of conjunctival neoplasia, recurrence or deep invasion require careful monitoring.
Char
Devron H
DH
The Tumori Foundation, 45 Castro Street, Suite 309, San Francisco, CA 94114, USA. devron@tumori.org
Crawford
J Brooks
JB
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000556:secondary*; D003230:Conjunctival Neoplasms / Q000188:drug therapy / Q000473:pathology*; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D016685:Mitomycin / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis*; D009918:Orbital Neoplasms / Q000175:diagnosis / Q000556:secondary*; D011994:Recombinant Proteins; D012189:Retrospective Studies
D000964:Antimetabolites, Antineoplastic; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D016685:Mitomycin; D005472:Fluorouracil